.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Colorectal cancer (CRC) remains a significant public health burden. Unfortunately, many patients avoid traditional screening methods such as colonoscopy or stool-based tests. Blood-based CRC screening offers a non-invasive alternative that could improve population health outcomes. By providing a simpler testing modality, healthcare providers can reach individuals who previously declined all screening options. Consequently, this approach may significantly reduce cancer-related mortality in the long term.
This study utilized a validated discrete-event simulation model to assess 10,000 individuals starting at age 45. Researchers analyzed clinical outcomes and cost-effectiveness from a healthcare sector perspective. Evidence from randomized controlled trials informed patient preferences for various screening options. Furthermore, the researchers modeled adherence using both ideal and longitudinal real-world scenarios. The findings indicate that adding blood tests to the screening arsenal yields substantial benefits. Specifically, CRC deaths averted increased between 68% and 247% in revealed preference scenarios compared to no screening.
Cost-effectiveness remains a critical factor for implementing any new medical technology. The analysis found that blood tests fall well within the standard willingness-to-pay threshold of $100,000 per quality-adjusted life-year (QALY). Incremental cost-effectiveness ratios (ICERs) ranged from $30,464 to $85,497 across different scenarios. Therefore, these tests provide high value while addressing the screening gap. Additionally, the non-invasive nature of the test helps patients overcome common psychological and logistical barriers associated with colonoscopy.
Despite these promising results, some limitations exist. The study relied on informed assumptions for natural history and longitudinal adherence due to limited real-world data. However, the simulation demonstrates that blood-based CRC screening can lead to cost-effective increases in life-saving outcomes. Healthcare systems should consider these findings when developing inclusive screening programs for resistant populations.
No, it serves as an alternative for patients who decline traditional methods, helping to increase overall screening rates and catch cancer earlier.
Blood tests are cost-effective because they significantly increase screening participation among individuals who otherwise would not be screened at all, reducing long-term treatment costs.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new economic evaluation shows that blood-based colorectal cancer screening is cost-effective and significantly reduces mortality among unscreened individu...
6 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
